Shiquan Xu; Qing Liu; Jie Wang; Zeyun Zhang; Ying Wang; Li Li; Tao Zhang; Yu Fan
Abstract
Background: Previous research has identified several potential biomarkers associated with pathological tumor (pT) staging in prostate cancer (PCa) patients. Among these biomarkers, CX3CR1 is notable for its connection to the immune microenvironment.Objective: To further investigate the significance of ...
Read More
Background: Previous research has identified several potential biomarkers associated with pathological tumor (pT) staging in prostate cancer (PCa) patients. Among these biomarkers, CX3CR1 is notable for its connection to the immune microenvironment.Objective: To further investigate the significance of CX3CR1 as a key biomarker for predicting pT staging and PCa progression.Methods: Prostate cancer tissue samples were analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemical staining. The diagnostic performance of CX3CR1 was evaluated using receiver operating characteristic (ROC) curves, while Kaplan–Meier survival analysis was conducted to determine overall survival (OS) rates.Results: A significant decrease in CX3CR1 expression was observed in PCa tissues compared to adjacent normal tissues, with the lowest levels detected in pT3 tumors. CX3CR1 expression showed a negative correlation with preoperative prostate-specific antigen (PSA) levels, lymph node staging (N stage), Gleason score, and overall survival (OS). Additionally, CX3CR1 levels were associated with the polarization of infiltrating CD4+ T cells in PCa patients.Conclusion: CX3CR1, as a biomarker associated with pT staging, plays a role in predicting PCa prognosis, potentially by modulating the immune microenvironment.
Mehdi Dehghani; Zohreh Mostafavi-Pour; Mehrzad Lotfi; Saeed Shakeri
Volume 6, Issue 2 , June 2009, , Pages 92-98
Abstract
Background: Prostate specific antigen (PSA) has been used as a screening test for the early detection of prostate cancer (PC) for many years. Although the introduction of PSA test led to a considerable increase in reported prostate cancer cases, there is still some controversy over the sensitivity and ...
Read More
Background: Prostate specific antigen (PSA) has been used as a screening test for the early detection of prostate cancer (PC) for many years. Although the introduction of PSA test led to a considerable increase in reported prostate cancer cases, there is still some controversy over the sensitivity and specificity of this marker in distinguishing PC patients from those with benign prostate hyperplasia (BPH), the most common benign prostate condition. Objective: An attempt is made to elucidate if the plasma level of Interleukin 8 (IL-8) could be used effectively as a marker for the detection of prostate cancer. Methods: Plasma levels of IL-8 and PSA were measured in two groups of 40 BPH and PC patients using enzyme-linked immunosorbent (ELISA) and radioimmunoassay (RIA) techniques, respectively. In addition IL-8 levels in PC3 and DU145 cell line supernatants were measured by ELISA technique. Results: The concentration of IL-8 in the plasma of PC patients was not significantly higher than the BPH subjects. Although, a correlation between plasma IL-8 concentration and the Gleason score of PC patients was found, no indicated correlation was detected between the concentration of IL-8 or PSA and age of the patients in both groups. DU145 and PC3 cell lines produced and secreted IL-8 in the media. Conclusion: Data of this investigation collectively conclude no correlation between IL-8 concentration in PC and BPH patients.
